Simplified Antibiotic Therapy for Sepsis in Young Infants (SATT)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This trial evaluates primary care clinic-based simplified antibiotic therapy options for young infants, 0-59 days old in high neonatal mortality settings in peri-urban Karachi where hospital referral is frequently refused by families.
| Condition | Intervention | Phase |
|---|---|---|
|
Neonatal Sepsis Sepsis Infection |
Drug: procaine penicillin and gentamicin Drug: amoxicillin and gentamicin Drug: procaine penicillin, gentamicin, amoxicillin |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Simplified Antibiotic Regimens for the Management of Sepsis in Young Infants in First-level Facilities: Randomized Controlled Trial |
- Treatment failure [ Time Frame: within 7 days of enrolment ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 2640 |
| Study Start Date: | December 2009 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: procaine penicillin and gentamicin
Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
|
Drug: procaine penicillin and gentamicin
procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
Drug: procaine penicillin, gentamicin, amoxicillin
procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
|
|
Experimental: Amoxicillin and gentamicin
Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
|
Drug: amoxicillin and gentamicin
oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
Drug: procaine penicillin, gentamicin, amoxicillin
procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
|
|
Experimental: procaine penicillin, gentamicin, and amoxicillin
procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
|
Drug: procaine penicillin, gentamicin, amoxicillin
procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
|
Detailed Description:
Primary Objective
To evaluate if out-patient (clinic-based) therapy of young infants with possible serious bacterial infection with 7 days of intramuscular procaine penicillin and gentamicin (reference therapy) is equivalent to:
- (1) injectable gentamicin once daily and oral amoxicillin twice daily for seven days;
- (2) injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days; and
Hypothesis
The proportion of babies who fail therapy at (or before 7) days will be 10% in each group. A 5% or less difference in failure rates will be considered equivalent.
Study Design
This will be a randomized, three arm, open-label equivalence trial among young infants, 0-59 days of age who are diagnosed as having possible serious bacterial infection in one of the Karachi field clinics, and whose families refuse facilitated hospital referral, and the infants meet other specified inclusion criteria.
Eligible young infants will be recruited from among those referred to the clinics by trained community health workers as having clinical signs predictive of possible serious illness during regular home visits in the surveillance area, or those presenting directly to the clinics from the areas under pregnancy and newborn surveillance. A diagnosis of possible sepsis will be made by clinicians if specified clinical criteria are met.
Eligibility| Ages Eligible for Study: | up to 59 Days |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Inclusion Criteria
- Infants 0-59 days old who are residents of catchment population of the study hospitals or clinics
- One or more of the following five signs: severe chest in-drawing, axillary temperature >38.0C or <35.50 C, movement only when stimulated, and history of feeding problems (confirmed by poor suck on feeding assessment)
- Family refuses recommended hospitalization or hospitalization otherwise not feasible
- Informed consent by a legal guardian.
- Exclusion Criteria:
Very severe infection/disease characterized by presence of any of the following signs (unconscious, convulsions, unable to feed, apnea, unable to cry, cyanosis, bulging fontanel, prolonged capillary refill, major congenital malformations, major bleeding, surgical conditions needing hospital referral, persistent vomiting defined as vomiting following three attempts to feed the baby within ½ hour)
- Very low birth weight: weight <1500
- Hospitalization for illness in the last two weeks
- Previous inclusion in the study
Contacts and Locations| Contact: Anita K.M Zaidi, MBBS, SM | 92-21-3493-0051 ext 4734 | anita.zaidi@aku.edu |
| Contact: Shiyam Sundar, MBBS | 92-21-3993-0051 ext 4955 | shiyam.sundar@aku.edu |
| Pakistan | |
| Anita K M Zaidi | Recruiting |
| Karachi, Sindh, Pakistan, 74800 | |
| Contact: Zaidi anita.zaidi@aku.edu | |
| Principal Investigator: Anita K. M Zaidi, MBBS, SM | |
More Information
No publications provided
| Responsible Party: | Anita Kaniz Mehdi Zaidi, Professor and Chair, Department of Paediatrics and Child Health, Aga Khan University |
| ClinicalTrials.gov Identifier: | NCT01027429 History of Changes |
| Other Study ID Numbers: | SC134GL50124 |
| Study First Received: | December 7, 2009 |
| Last Updated: | April 2, 2012 |
| Health Authority: | United States: International Technical Steering Committee appointed by Save the Children, USA, and Switzerland: World Health Organization |
Keywords provided by Aga Khan University:
|
infant newborn sepsis infection community |
Additional relevant MeSH terms:
|
Sepsis Toxemia Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes Amoxicillin Anti-Bacterial Agents Gentamicins Penicillin G Penicillin G Benzathine Penicillin G Procaine Procaine |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 17, 2013